Literature DB >> 15697096

Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey.

William H Shrank1, Henry N Young, Susan L Ettner, Peter Glassman, Steven M Asch, Richard L Kravitz.   

Abstract

BACKGROUND: Three-tier pharmaceutical benefit systems use graded co-payments to steer patients toward "preferred" formulary medications.
OBJECTIVES: To evaluate physicians' knowledge of formularies and out-of-pocket costs in such systems, as well as their perceived responsibility for helping patients manage out-of-pocket costs. STUDY
DESIGN: Self-administered written survey.
METHODS: Physician leaders participating in the California Medical Association Leadership Conference were surveyed.
RESULTS: A total of 133 responses were received from 205 participants (65% response rate). Physicians reported that they were often unaware of patients' out-of-pocket costs at the time of prescribing. Fifty-nine percent of physicians reported that they never or seldom were aware of patients' "preferred" (lower cost) formulary options when prescribing, and 70% never or seldom were aware of patients' out-of-pocket costs when prescribing. Although 88% of physicians agreed that it is important that patients' out-of-pocket costs for prescription drugs are managed, only 25% strongly or somewhat agreed that it is their "responsibility" to help. Instead, 69% of physicians believed that it is the responsibility of the pharmacist to be familiar with patients' out-of-pocket costs. Physicians reported that they receive phone calls from pharmacists concerning formulary issues after 18.6% of the prescriptions they write.
CONCLUSIONS: Physician leaders reported that they often do not possess the knowledge to assist patients in managing out-of-pocket costs for prescription drugs and they depend on pharmacists to communicate patient preferences in making prescribing decisions. As a result, price preferences are communicated indirectly, likely less efficiently, rather than intentionally when prescribing decisions are made.

Entities:  

Mesh:

Year:  2005        PMID: 15697096

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  10 in total

1.  Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.

Authors:  M Christopher Roebuck; Joshua N Liberman
Journal:  Health Serv Res       Date:  2009-01-28       Impact factor: 3.402

2.  The effect of pharmacy benefit design on patient-physician communication about costs.

Authors:  William H Shrank; Sarah A Fox; Adele Kirk; Susan L Ettner; Clairessa H Cantrell; Peter Glassman; Steven M Asch
Journal:  J Gen Intern Med       Date:  2006-04       Impact factor: 5.128

3.  A comparison of drug formularies and the potential for cost-savings.

Authors:  Andrea L Kjos; Jon C Schommer; Yingli Yuan
Journal:  Am Health Drug Benefits       Date:  2010-09

4.  Types of information physicians provide when prescribing antidepressants.

Authors:  Henry N Young; Robert A Bell; Ronald M Epstein; Mitchell D Feldman; Richard L Kravitz
Journal:  J Gen Intern Med       Date:  2006-11       Impact factor: 5.128

5.  Association of income and prescription drug coverage with generic medication use among older adults with hypertension.

Authors:  Alex D Federman; Ethan A Halm; Carolyn Zhu; Tsivia Hochman; Albert L Siu
Journal:  Am J Manag Care       Date:  2006-10       Impact factor: 2.229

6.  Whom do older adults trust most to provide information about prescription drugs?

Authors:  Julie M Donohue; Haiden A Huskamp; Ira B Wilson; Joel Weissman
Journal:  Am J Geriatr Pharmacother       Date:  2009-04

7.  Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use.

Authors:  William H Shrank; Margaret Stedman; Susan L Ettner; Dee DeLapp; June Dirstine; M Alan Brookhart; Michael A Fischer; Jerry Avorn; Steven M Asch
Journal:  J Gen Intern Med       Date:  2007-07-24       Impact factor: 5.128

8.  Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?

Authors:  William H Shrank; Suzanne M Cadarette; Emily Cox; Michael A Fischer; Jyotsna Mehta; Alan M Brookhart; Jerry Avorn; Niteesh K Choudhry
Journal:  Med Care       Date:  2009-03       Impact factor: 2.983

9.  Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.

Authors:  Pengxiang Li; J Sanford Schwartz; Jalpa A Doshi
Journal:  J Am Heart Assoc       Date:  2016-11-11       Impact factor: 5.501

10.  What is in your wallet? A cluster randomized trial of the effects of showing comparative patient out-of-pocket costs on primary care prescribing for uncomplicated hypertension.

Authors:  Robyn Tamblyn; Nancy Winslade; Christina J Qian; Teresa Moraga; Allen Huang
Journal:  Implement Sci       Date:  2018-01-10       Impact factor: 7.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.